@article {Tan2021.01.24.21250074, author = {Hyon-Xhi Tan and Wen Shi Lee and Kathleen M Wragg and Christina Nelson and Robyn Esterbauer and Hannah G Kelly and Thakshila Amarasena and Robert Jones and Graham Starkey and Bao Zhong Wang and Osamu Yoshino and Thomas Tiang and M Lindsay Grayson and Helen Opdam and Rohit D{\textquoteright}Costa and Angela Vago and The Austin Liver Transplant Perfusionist Group and Laura K Mackay and Claire L Gordon and Adam K Wheatley and Stephen J Kent and Jennifer A Juno}, title = {Adaptive immunity to human coronaviruses is widespread but low in magnitude}, elocation-id = {2021.01.24.21250074}, year = {2021}, doi = {10.1101/2021.01.24.21250074}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Endemic human coronaviruses (hCoV) circulate worldwide but cause minimal mortality. Although seroconversion to hCoV is near ubiquitous during childhood, little is known about hCoV-specific T cell memory in adults. We quantified CD4 T cell and antibody responses to hCoV spike antigens in 42 SARS-CoV-2 uninfected individuals. T cell responses were widespread within conventional memory and cTFH compartments but did not correlate with IgG titres. SARS-CoV-2 cross-reactive T cells were observed in 48\% of participants and correlated with HKU1 memory. hCoV-specific T cells exhibited a CCR6+ central memory phenotype in the blood, but were enriched for frequency and CXCR3 expression in human lung draining lymph nodes. Overall, hCoV-specific humoral and cellular memory are independently maintained, with a shared phenotype existing among coronavirus-specific CD4 T cells. This understanding of endemic coronavirus immunity provides insight into the homeostatic maintenance of immune responses that are likely to be critical components of protection against SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by the Victorian Government, a Doherty Collaborative Research Award (JJ), the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (SJK), an NHMRC program grant APP1149990 (SJK), and philanthropic support from the Paul Ramsay Foundation (SJK and AKW). AKW is funded by an NHMRC Investigator grant. JAJ and SJK are funded by NHMRC fellowships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the University of Melbourne Human Research Ethics Committee ($\#$2056689).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available from the authors upon reasonable request}, URL = {https://www.medrxiv.org/content/early/2021/01/26/2021.01.24.21250074}, eprint = {https://www.medrxiv.org/content/early/2021/01/26/2021.01.24.21250074.full.pdf}, journal = {medRxiv} }